Accessibility Menu
Rafael logo

Rafael(NYSE) RFL

Market Cap$100.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-60%
5 Year-96%
1 Year+15%
1 Month-49%
$1.96
-2.00%
-0.04Today
Rafael last closing stock price
MetricPriceDate
Last closeUSD 1.942026-07-31
Rafael stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-8.92%USD 2.132026-07-24
1 month-48.68%USD 3.782026-07-01
3 month+56.45%USD 1.242026-05-01
Year to date+64.41%USD 1.182025-12-31
1 year+14.79%USD 1.692025-07-31
3 year-4.43%USD 2.032023-08-01
5 year-96.17%USD 50.612021-07-30
Since inception-59.84%USD 4.832018-03-27

Rafael Financials at a Glance

Market Cap

$100.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$980.00K

Net Income (TTM)

-$32.55M

EPS (TTM)

-$0.68

P/E Ratio

-2.85

Dividend

$0.00

Beta (Volatility)

0.71 (Low)

Price

$1.96

Volume

60,244

Open

$2.05

Previous Close

$1.94

Daily Range

$1.92 - $2.05

52-Week Range

$1.12 - $3.96

Estimated Earnings Date

Jun 11, 2026

RFL News

stock-chart-dropping-explanation

Here's Why Rafael Holdings Is Plummeting Today

Cory RenauerOct 28, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Rafael

Rafael Holdings develops new medicines for rare diseases and cancer. It also owns and leases commercial real estate in Israel. Its products help patients with hard-to-treat illnesses and provide office space for businesses.

What’s in the Rafael Toolbox?

  • Healthcare: Develops drugs for rare diseases and cancer, serving hospitals and research centers.
  • Infusion Technology: Manufactures cannabinoid ingredient technology for pharmaceutical and wellness companies.
  • Real Estate: Leases office space and a public parking garage in Jerusalem, targeting local businesses and organizations.
  • Orthopedic Devices: Produces minimally invasive surgical tools for hospitals and clinics.
  • Cancer Metabolism Research: Invests in early-stage research to find new cancer treatments.

Growth Moves: Rafael’s Recent Plot Twists

  • Acquired Cyclo Therapeutics in March 2025, making Trappsol® Cyclo™ its lead drug program.
  • Bought controlling interest in Cornerstone Pharmaceuticals in March 2024, expanding cancer drug research.
  • Secured FDA clearance for the VECTR orthopedic device in December 2024.
  • Acquired Day Three Labs in January 2024, entering cannabinoid technology.
  • Sold all available-for-sale securities in November 2024 to reallocate assets.

Why Rafael Is a Bit Different

Rafael combines drug development for rare diseases with steady real estate income. Its small size allows quick shifts in strategy and focus. The company’s mix of healthcare, technology, and property is unusual for its sector.

Five Things You Need to Know

  • Revenue was $350,000 in Q4 2025, up 112.1% from Q4 2024.
  • Net loss was $13 million in Q4 2025, down from $4 million in Q4 2024.
  • Cash flow from operations was negative $10 million in Q4 2025, down 259.3% year-on-year.

Bottom Line

Rafael has shifted from real estate to focus on rare disease and cancer drug development. Its diverse assets and recent acquisitions show adaptability in a challenging market.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

23

CEO

Howard S. Jonas

Website

www.rafaelholdings.com

Headquarters

Newark, NJ 07102, US

RFL Financials

Key Financial Metrics (TTM)

Gross Margin

84.39%

Operating Margin

-3717.24%

Net Income Margin

-3321.73%

Return on Equity

-38.97%

Return on Capital

-27.46%

Return on Assets

-35.39%

Earnings Yield

-35.09%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$100.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

52.00M

Volume

60.24K

Avg. Volume

197.04K

Financials (TTM)

Gross Profit

$827.00K

Operating Income

-$36.43M

EBITDA

-$31.00M

Operating Cash Flow

-$31.98M

Capital Expenditure

-$4.00K

Free Cash Flow

-$31.98M

Cash & ST Invst.

$30.50M

Total Debt

$610.00K

Rafael Performance Analysis

Rafael annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-07-31USD 410,000N/A
20232023-07-31USD 279,000-32.0%
20242024-07-31USD 637,000128.3%
20252025-07-31USD 917,00044.0%
Rafael sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-07-31-3.3%
Q12025-10-31-31.4%
Q22026-01-31-12.1%
Q32026-04-30-15.2%
Rafael annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-07-31USD -6.22N/A
20232023-07-31USD -0.37-94.1%
20242024-07-31USD -1.43289.3%
20252025-07-31USD -1.04-27.4%
Rafael sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-07-31-47.4%
Q12025-10-3132.1%
Q22026-01-3131.6%
Q32026-04-3036.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

$179.00K

-50.6%

Gross Profit

$171.00K

-46.9%

Gross Margin

95.53%

N/A

Market Cap

$100.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.39M

N/A

Employees

23

N/A

Net Income

-$4.23M

+11.6%

EBITDA

-$2.84M

+54.5%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

$30.50M

-19.6%

Total Debt

$610.00K

-11.6%

Accounts Receivable

$294.00K

-29.0%

Inventory

$276.00K

-4.2%

Long Term Debt

$2.00K

-97.4%

Short Term Debt

$608.00K

-1.0%

Return on Assets

-35.39%

N/A

Return on Invested Capital

-44.99%

N/A

Free Cash Flow

-$7.28M

-129.0%

Operating Cash Flow

-$7.28M

-128.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SOHOSotherly Hotels Inc.
$2.25+0.45%
FTHMFathom Holdings Inc.
$0.80+0.38%
AHTAshford Hospitality Trust, Inc.
$3.23+0.31%
OPADOfferpad Solutions Inc.
$3.87-6.75%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About RFL

What is the current price of Rafael?

Rafael is trading at $1.94 per share.

What is the 52-week range for Rafael?

Over the past 52 weeks, Rafael has traded between $1.12 and $3.96.

How much debt does Rafael have?

As of the most recent reporting period, Rafael reported total debt of $610.00K.

How much cash does Rafael have on hand?

Rafael reported $30.50M in cash and cash equivalents in its most recent financial results.

What is Rafael’s dividend yield?

Rafael does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services